<DOC>
	<DOCNO>NCT02970162</DOCNO>
	<brief_summary>This study evaluate effect withdraw amifampridine phosphate treatment patient LEMS . One half patient continue receive amifampridine phosphate half receive placebo , double-blind study .</brief_summary>
	<brief_title>Phase 3 Study Evaluate Efficacy Amifampridine Phosphate Lambert-Eaton Myasthenic Syndrome ( LEMS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lambert-Eaton Myasthenic Syndrome</mesh_term>
	<criteria>1 . Male female â‰¥18 year age currently receive amifampridine phosphate LEMS . 2 . Diagnosis LEMS antibody test electromyography ( EMG ) . 3 . Completion anticancer treatment least 3 month ( 90 day ) prior Screening . 4 . If receive peripherally act cholinesterase inhibitor ( e.g . pyridostigmine ) , stable dose cholinesterase inhibitor require least 7 day prior randomization throughout study . 5 . If receive permit oral immunosuppressant ( prednisone corticosteroid ) , stable dose require least 30 day prior randomization throughout study . 6 . Female patient childbearing potential must practice effective , reliable contraceptive regimen study . 7 . Able perform study procedures assessment . 8 . Willing able travel study site attend clinic study visit . 9 . Willing able provide write informed consent . 1 . Clinically significant long correct QT ( QTc ) interval ECG previous 12 month . 2 . Seizure disorder . 3 . Active brain metastasis . 4 . Unable ambulate . 5 . Pregnant lactating female . 6 . Any condition , opinion Investigator , might interfere patient 's participation study confound assessment patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>LEMS</keyword>
</DOC>